OpenNashEarnings

Cigna Group (CI) · Health Insurance

Cigna Group Q2 2026 earnings: summary, key numbers & outlook

Results filed 30 Jul 2026 · Quarter ended 30 Jun 2026

Official transcript (PDF) ↗Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

Cigna is exiting Individual and Family Plans from January 2027 while Evernorth's specialty business grows on biosimilar and generic adoption and pharmacy benefit margins absorb large client renewals.

Cigna Healthcare grew medical customers to 18.4 million, led by Middle and Select markets, while National Accounts membership declined. Premium increases drove growth in the employer business, which also saw better margins. At Evernorth, specialty volume was strong, helped by higher generic and biosimilar use that lowers costs for clients and patients. Pharmacy customers fell to 118.2 million on expected client transitions and lower health plan membership.

Management is steering toward technology, data and AI to personalize customer experiences, widen access and cut costs, and is trimming the portfolio by leaving Individual and Family Plans on January 1, 2027. The main tension is in pharmacy benefits, where large client contract renewals and customer-focused initiatives are cutting profit even as revenue grows, while pharmacy membership keeps shrinking.

Key numbers

Total revenues · GAAP
$71.7 billion

up 7% from a year ago

Shareholders' net income · GAAP
$1.7 billion

Diluted EPS · GAAP
$6.29

compared to $5.71 for second quarter 2025

Adjusted income from operations per share · non-GAAP
$7.78

compared with $7.20 for second quarter 2025

Segment or metricValueChange
Cigna Healthcare medical care ratio84.5%compared to 83.2% for second quarter 2025
Where each number comes from
  • Total revenues: “Total revenues for the second quarter 2026 increased 7% to $71.7 billion”
  • Shareholders' net income: “Shareholders’ net income for the second quarter 2026 was $1.7 billion, or $6.29 per share”
  • Diluted EPS: “Shareholders’ net income for second quarter 2026 was $1.7 billion, or $6.29 per share compared to $1.5 billion, or $5.71 per share, for second quarter 2025”
  • Adjusted income from operations per share: “adjusted income from operations1 for second quarter 2026 was $2.1 billion, or $7.78 per share, compared with $1.9 billion, or $7.20 per share, for second quarter 2025”
  • Cigna Healthcare medical care ratio: “The Cigna Healthcare MCR4 was 84.5% for second quarter 2026, compared to 83.2% for second quarter 2025”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

From the filingQ2 2026vs year agovs last quarter
Revenue$71.7B+6.7%+4.6%
Operating income$2.7B+16.0%+13.5%
Net income$1.7B+8.4%+0.4%
Diluted EPS$6.29+10.2%+0.5%
Operating margin3.7%+0.3 pts+0.3 pts

Calculated by code from XBRL, not by the model.

Outlook

MetricPeriodOutlook
Adjusted income from operations per sharefull year 2026at least $30.45
Evernorth adjusted income from operations, pre-taxfull year 2026at least $6,900
Cigna Healthcare adjusted income from operations, pre-taxfull year 2026at least $4,550
Cigna Healthcare medical care ratiofull year 202683.7% to 84.7%

Key takeaways

  1. Cigna will exit Individual and Family Plans

    The company announced in April 2026 that it will leave the Individual and Family Plans medical business as of January 1, 2027. This narrows Cigna Healthcare toward employer-focused markets.

  2. Specialty growth is driven by volume and biosimilars

    Specialty and Care Services saw strong specialty volume growth and higher generic and biosimilar adoption, which the company says lowers costs for clients and patients. Pre-tax operating income rose 22%.

  3. Pharmacy benefit profits fall on client renewals

    Pharmacy Benefit Services pre-tax income fell 27%, reflecting large client contract renewals and customer-focused initiatives, consistent with prior commentary. Revenue still rose 8% on drug mix.

  4. Medical membership grows in Middle and Select

    Total medical customers rose 2% since year-end to 18.4 million, with gains in Middle and Select markets partly offset by lower National Accounts membership.

  5. Pharmacy customer base shrinks on client transitions

    Pharmacy customers fell 4% since year-end to 118.2 million, reflecting expected client transitions and lower membership from health plan clients. This leaves the company with fewer pharmacy relationships even as it pursues AI-led personalization.

Charts

Revenue$71.7B+6.7% y/yQ2 2026
Q4 2024: $65.6B (worked out from the annual figure)Q4 ’24$65.6BQ1 2025: $65.5BQ1 ’25$65.5BQ2 2025: $67.2BQ2 ’25$67.2BQ3 2025: $69.7BQ3 ’25$69.7BQ4 2025: $72.5B (worked out from the annual figure)Q4 ’25$72.5BQ1 2026: $68.5BQ1 ’26$68.5BQ2 2026: $71.7BQ2 ’26$71.7BQ3 2026: $73.7BQ3 ’26$73.7B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$65.6B *
Q1 2025$65.5B
Q2 2025$67.2B
Q3 2025$69.7B
Q4 2025$72.5B *
Q1 2026$68.5B
Q2 2026$71.7B
Q3 2026$73.7B
Diluted EPS (GAAP)$6.29+10.2% y/yQ2 2026
Q1 2025: $4.85Q1 ’25$4.85Q2 2025: $5.71Q2 ’25$5.71Q3 2025: $6.98Q3 ’25$6.98Q1 2026: $6.26Q1 ’26$6.26Q2 2026: $6.29Q2 ’26$6.29Q3 2026: $5.47Q3 ’26$5.47
Data
Q1 2025$4.85
Q2 2025$5.71
Q3 2025$6.98
Q1 2026$6.26
Q2 2026$6.29
Q3 2026$5.47

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin3.7%+0.3 pts y/yQ2 2026
Q4 2024: 3.3%Q4 ’243.3%Q1 2025: 3.0%Q1 ’253.0%Q2 2025: 3.4%Q2 ’253.4%Q3 2025: 3.7%Q3 ’253.7%Q4 2025: 3.2%Q4 ’253.2%Q1 2026: 3.4%Q1 ’263.4%Q2 2026: 3.7%Q2 ’263.7%Q3 2026: 3.3%Q3 ’263.3%
Data
Q4 20243.3%
Q1 20253.0%
Q2 20253.4%
Q3 20253.7%
Q4 20253.2%
Q1 20263.4%
Q2 20263.7%
Q3 20263.3%

Questions

What is Cigna doing with its Individual and Family Plans business?

Cigna announced in April 2026 that it plans to exit the Individual and Family Plans medical business as of January 1, 2027.

Why did pharmacy benefit profit fall?

Pharmacy Benefit Services pre-tax income fell 27% because of client-focused initiatives, including large client contract renewals, and customer-focused initiatives, consistent with prior commentary.

What is driving growth in Cigna's specialty business?

Strong specialty volume growth and organic growth in specialty businesses, including higher generic and biosimilar adoption, drove the segment's results.

How did Cigna's customer base change this quarter?

Medical customers rose 2% since December 31, 2025 to 18.4 million on Middle and Select market growth, while pharmacy customers fell 4% to 118.2 million.

Where is Cigna focusing its strategy?

Management said it is using technology, data and AI to deliver more personalized experiences, improve access and lower costs.

Documents

From Cigna Group investor relations

SEC filing